Denosumab vs. Bisphosphonates for Osteoporosis from Glucocorticoids
Author Information
Author(s): Chen Chiao-Ling, Wang Jian-Ying
Primary Institution: Department of Pharmacy, Taipei City Hospital, Taipei, Taiwan; Department of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan
Hypothesis
Is denosumab more effective than bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis?
Conclusion
Denosumab is more effective than bisphosphonates in increasing bone mineral density in patients with glucocorticoid-induced osteoporosis while maintaining a similar safety profile.
Supporting Evidence
- Denosumab showed a significant mean difference in BMD percentage change from baseline at lumbar spine of 2.87%.
- At the total hip, denosumab had a mean difference of 1.39% compared to bisphosphonates.
- The safety profile of denosumab was comparable to bisphosphonates with no significant increase in adverse events.
Takeaway
This study found that a medicine called denosumab works better than another medicine called bisphosphonates for people who have weak bones because of steroid use.
Methodology
A systematic review and meta-analysis of randomized controlled trials comparing denosumab and bisphosphonates for glucocorticoid-induced osteoporosis.
Potential Biases
Concerns about bias due to lack of blinding in most studies.
Limitations
The study faced limitations such as heterogeneity among included studies and the need for longer-term research.
Participant Demographics
Participants aged 48.0 to 68.5 years, with varying prior treatments and conditions.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 1.86 to 3.87
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website